Last reviewed · How we verify

NCT05051384: SMITIS

Superb Microvascular Intraocular Tumor Imaging Study (SMITIS)

Active, enrolled NA Last updated 3 December 2025
What this trial tests

NA trial testing Doppler technology in Ocular Tumor in 22 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
27 April 2022
Primary endpoint
27 April 2023
18 January 2026

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Nice
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment22
Start date27 April 2022
Primary completion27 April 2023
Estimated completion18 January 2026
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Nice

Who can join

Adults 18 to 99, any sex, with Ocular Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The diagnosis and monitoring of intraocular tumors are based on multimodal imaging in addition to the clinical examination (ultra-widefield retinal imaging, echography, angiography). Nevertheless, it may be difficult in cases of retinal hemorrhage, small tumor size or atypical presentation. The study of microvascular flow (Superb Microvascular Imaging, SMI) of intraocular tumors could improve the confidence of differential diagnosis when evaluating these suspicious lesions, or even determine whether a lesion is benign or malignant by describing the vascularization of the lesion. The investigators propose to study the microvascular flow patterns of intraocular tumors prior to proton therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ocular Tumor

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Nice trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05051384.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing